Compare Hilton Hotels Corporation Common Stock (HLT) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Hilton Hotels Corporation Common Stock trades at $330.2 (market cap $74.18B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 9.9× Spyre Therapeutics Inc. Common Stock's market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 139 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HLT | SYRE | |
|---|---|---|
Market Cap | $74.18B | $7.52B |
Volume | 1,295,545 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $108.92 |
52-Week Low | $256.96 | $22.18 |
Typical Hold Time | 139 Days | 0 Days |
Enterprise Value | $87.19B | $6.52B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $328.12, up 0.18% on the day, with strong technical momentum as the stock approaches resistance near $330. The company demonstrates solid fundamental performance with revenue growth from $12.04B in 2025 to projected $12.5B in 2026, consistently beating earnings expectations in recent quarters. Analyst sentiment remains bullish with 57% buy ratings and a $350 consensus price target, supported by institutional accumulation and positive travel industry trends.
HLT presents a compelling investment case with strong earnings momentum and global portfolio expansion, though elevated valuation metrics (P/E 48.4) and rising debt levels warrant caution. The stock's proximity to technical resistance and overbought RSI readings suggest potential near-term consolidation before further upside toward analyst targets. Key risks include macroeconomic sensitivity and competitive pressures in the hospitality sector.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
